arrow
M

Melhem Solh

northside hospital cancer institute
H指数:42
被引数:6,252

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

在费城染色体阳性急性淋巴细胞白血病中使用Brexucabtagene Autoleucel治疗后,TKI维持疗法可改善疗效

2026-06-290
OA
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 独立预测急性淋巴细胞白血病接受CD19 CAR-T疗法后的结局

2025-10-080
OAAI
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

CD19 CAR T细胞疗法治疗原发性纵隔大B细胞淋巴瘤:一项CIBMTR分析

2025-08-110
PRE
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia

移植预处理、NPM1突变及FLT3-ITD急性髓系白血病中可测量的微小残留病的影响

2025-07-030
OAAI
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Brexucabtagene autoleucel在伴有CNS受累的复发/难治性急性淋巴细胞白血病患者中的疗效

2025-05-090
OAAI
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703

基于移植后环磷酰胺的GVHD预防在70岁及以上患者中的影响:BMT CTN 1703的更新

2025-05-050
OA
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
2024-12-102
OAAI
Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant

成人费城染色体样急性淋巴细胞白血病(Ph-Like ALL)患者在接受整合白血病/移植项目治疗并采用儿童启发式方案及早期异基因移植后的改善结局

BLOOD
IF23.1
2024-11-050
PRE
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Brexucabtagene autoleucel治疗60岁及以上患者复发/难治性B细胞急性淋巴细胞白血病的有效性与安全性

BLOOD
IF23.1
2024-11-051
PRE
High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

供者HLA-B基因座的高HLA进化分歧会影响含移植后环磷酰胺的半相合造血细胞移植的移植结局。

BLOOD
IF23.1
2024-11-050
PRE
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
2024-08-142
OAAI
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

在LOTIS-2临床试验中接受loncastuximab tesirine治疗的老年和年轻患者的临床结果

2023-12-282
OAAI